ALBIREO PHARMA
Albireo Pharma is a rare disease company dedicated to the discovery and development of novel bile acid modulators for the treatment of pediatric and adult liver diseases.
ALBIREO PHARMA
Industry:
Biotechnology Health Care Therapeutics
Founded:
2008-01-01
Address:
Gothenburg, Vastra Gotaland, Sweden
Country:
Sweden
Website Url:
http://www.albireopharma.com
Total Employee:
101+
Status:
Active
Contact:
46 3 17 41 14 80
Total Funding:
85 M USD
Technology used in webpage:
Domain Not Resolving Microsoft Microsoft Azure Mailgun Microsoft Azure US East Region Getty Images Telenor
Similar Organizations
Alios BioPharma
Alios BioPharma is a biotechnology company developing novel medicines for the treatment of viral diseases.
Beren Therapeutics
Beren Therapeutics is a biotechnology company that develops innovative therapies to make them accessible to every patient.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Forge Therapeutics
Forge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry.
Numab
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-05-24 | Biodel | Biodel acquired by Albireo Pharma | N/A |
Investors List
TVM Capital
TVM Capital investment in Series A - Albireo Pharma
TPG Growth
TPG Growth investment in Series A - Albireo Pharma
Key Employee Changes
| Date | New article |
|---|---|
| 2022-12-06 | Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors |
Official Site Inspections
http://www.albireopharma.com Semrush global rank: 2.18 M Semrush visits lastest month: 9.18 K
- Host name: server-18-164-124-81.jfk50.r.cloudfront.net
- IP address: 18.164.124.81
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Albireo Pharma"
Albireo Pharma, Inc Company Profile | Management and
SQL International Organization for Standardization . CSS World Wide Web Consortium . HTML Web Hypertext Application Technology Working Group . R The R Foundation . ...See details»
Albireo Pharma - Crunchbase Company Profile
Albireo Pharma is a rare disease company dedicated to the discovery and development of novel bile acid modulators for the treatment of pediatric and adult liver diseases.See details»
Ipsen to Acquire Albireo - Growth in Rare Disease - Global
Jan 9, 2023 For more information on Albireo, please visit www.albireopharma.com. About Ipsen . Ipsen is a global, mid-sized biopharmaceutical company focused on transformative …See details»
Albireo Pharma, Inc. - AnnualReports.com
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and …See details»
Albireo Pharma - Craft
Mar 2, 2023 Albireo Pharma has 4 employees across 2 locations and $40.58 m in annual revenue in FY 2021. See insights on Albireo Pharma including office locations, competitors, …See details»
Albireo Pharma, Inc. Company Overview, Contact Details
May 24, 2017 Jun 23, 2022 | ir.albireopharma.com Albireo Pharma, Inc. hired Horn as chief medical officer on Jul 1st '18. Mr. Horn, who led studies that contributed to the evidence …See details»
Albireo Pharma Inc - Company Profile and News - Bloomberg …
Company profile page for Albireo Pharma Inc including stock price, company news, executives, board members, and contact informationSee details»
Albireo Announces Changes to R&D Organization - Yahoo Finance
Dec 9, 2021 Albireo Announces Changes to R&D Organization. Albireo Pharma, Inc. Thu, Dec 9, 2021, 9:00 AM 7 min read. ... For more information on Albireo, please visit …See details»
Albireo Pharma - Overview, News & Similar companies - ZoomInfo
Sep 19, 2023 Albireo Presents New Bylvay® (odevixibat) Data at Annual ESPGHAN Congress BOSTON, June 24, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a …See details»
Albireo Announces Changes to R&D Organization - GlobeNewswire
Dec 9, 2021 The Boston Business Journal named Albireo one of the 2019 and 2020 Best Places to Work in Massachusetts. For more information on Albireo, please visit …See details»
Albireo Appoints New Members to Board of Directors - Yahoo …
Aug 10, 2022 – Habib Dable, Former President and CEO of Acceleron Pharma, and Susan Alesina, Vice President, National Business Development and Alliances at Boston Children’s …See details»
Albireo Expands Leadership with Joan Connolly as Chief …
For more information on Albireo, please visit www.albireopharma.com. Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the …See details»
Ipsen Global - A Biopharmaceutical Company | Innovation for …
Nov 18, 2024 Ipsen is a global biopharmaceutical company focused on innovation and specialty care to improve the lives of patients around the world.See details»
Albireo Pharma : Ipsen to acquire Albireo accelerating growth in …
Jan 9, 2023 For more information on Albireo, please visit www.albireopharma.com. About Ipsen. Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines …See details»
Albireo Appoints Paul Streck, M.D., as Chief Medical Officer
– Dr. Craig Hopkinson, currently EVP of Research & Development and Chief Medical Officer at Alkermes, brings strong global orphan drug development expertise – Dr. Paul Streck, former …See details»
Albireo Announces Positive Topline Data from Phase 1 Study
Dec 16, 2021 The Boston Business Journal named Albireo one of the 2019 and 2020 Best Places to Work in Massachusetts. For more information on Albireo, please visit …See details»
Albireo Expands Leadership with Joan Connolly as Chief
Apr 13, 2021 For more information on Albireo, please visit www.albireopharma.com. Forward-Looking Statements This press release includes “forward-looking statements” within the …See details»
Albireo Announces Exclusive Licensing Agreement with Jadeite …
BOSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, entered into an exclusive …See details»
Albireo Reports Q1 Financial Results and Business Update
May 6, 2021 March 31, December 31, 2021 2020: Assets Current assets: Cash and cash equivalents $ 217,081 $ 251,272: Prepaid expenses and other current assetsSee details»
Albireo Announces Positive Topline Data from Phase 1 Study of …
Dec 16, 2021 The study met its primary objectives with data showing A3907 overall to be safe and well tolerated, with no serious adverse events (SAEs) or discontinuations due to treatment …See details»